## Supplemental Material

Table S1. Patient and Clinical Characteristics by Covid-19 Testing, and Test Results Among Patients with Hypertension\* (N=824,650).

	Total (N=824,650) Row Percent=	Covid-19 Testing, No (N=807,752)	Covid-19 Testing, Yes (N=16,898)	Test Negative (N=15,104)	Test Positive (N=1,794)
	100%	98%	2.0%	89.4%	10.6%
Age in years	64.4 (13.56)	64.4 (13.54)	64.3 (14.37)	64.7 (14.44)	61.3 (13.42)
18-39	35067 (4.3%)	34294 (4.2%)	773 (4.6%)	683 (4.5%)	90 (5%)
40-64	363493 (44.1%)	355836 (44.1%)	7657 (45.3%)	6635 (43.9%)	1022 (57%)
65-85	382794 (46.4%)	375537 (46.5%)	7257 (42.9%)	6659 (44.1%)	598 (33.3%)
85+	43296 (5.3%)	42085 (5.2%)	1211 (7.2%)	1127 (7.5%)	84 (4.7%)
Men	397941 (48.3%)	390351 (48.3%)	7590 (44.9%)	6743 (44.6%)	847 (47.2%)
Race/ethnicity					
Asian	105040 (12.7%)	102725 (12.7%)	2315 (13.7%)	1976 (13.1%)	339 (18.9%)
Black	102667 (12.4%)	100230 (12.4%)	2437 (14.4%)	2208 (14.6%)	229 (12.8%)
Hispanic	270287 (32.8%)	264683 (32.8%)	5604 (33.2%)	4743 (31.4%)	861 (48%)
Other/Unknown	26053 (3.2%)	25679 (3.2%)	374 (2.2%)	343 (2.3%)	31 (1.7%)
White	320603 (38.9%)	314435 (38.9%)	6168 (36.5%)	5834 (38.6%)	334 (18.6%)
Neighborhood Income	1 452205 (49 59/)	140044 (40 40/)	2264 (40.0%)	2047 (40.00/)	E44 (20 <b>7</b> 0/ )
\$0-49k	152205 (18.5%)	148844 (18.4%)	3361 (19.9%)	2847 (18.8%)	514 (28.7%)
\$50-79k	308061 (37.4%)	301712 (37.4%)	6349 (37.6%)	5670 (37.5%)	679 (37.8%)
\$80-99k	165677 (20.1%)	162239 (20.1%)	3438 (20.3%)	3106 (20.6%)	332 (18.5%)
≥\$100k	197393 (23.9%)	193661 (24%)	3732 (22.1%)	3467 (23%)	265 (14.8%)
Missing	1314 (0.2%)	1296 (0.2%)	18 (0.1%)	14 (0.1%)	4 (0.2%)
Neighborhood Education (			FC4 (2.20()	440 (00()	110 (0 50()
0-50%	25674 (3.1%)	25110 (3.1%)	564 (3.3%)	448 (3%)	116 (6.5%)
51-75%	202823 (24.6%)	198460 (24.6%)	4363 (25.8%)	3726 (24.7%)	637 (35.5%)
76-100%	594879 (72.1%)	582925 (72.2%)	11954 (70.7%)	10917 (72.3%)	1037 (57.8%)
Insurance Type Commercial	200727 (47 40/)	380548 (47.1%)	0100 (40 50/)	7086 (46.9%)	1103 (61.5%)
	388737 (47.1%) 281441 (34.1%)	276028 (34.2%)	8189 (48.5%) 5413 (32%)	4928 (32.6%)	
Private pay Medicare		128561 (15.9%)		2556 (16.9%)	485 (27%) 143 (8%)
Medicaid	131260 (15.9%) 22935 (2.8%)	22340 (2.8%)	2699 (16%)	, ,	63 (3.5%)
Other/Missing	277 (0.03%)	275 (0.03%)	595 (3.5%) 2 (0.01%)	532 (3.5%) 2 (0.01%)	63 (3.5%)
· ·	30.8 (6.93)		, ,	, ,	- 22.0 (7.20)
Body Mass Index (kg/m²)	, ,	30.8 (6.92)	31.1 (7.53)	31.0 (7.55)	32.0 (7.28)
<25	136795 (16.6%)	133638 (16.5%)	3157 (18.7%)	2923 (19.4%)	234 (13%)
25-29.9	241392 (29.3%)	236532 (29.3%)	4860 (28.8%)	4376 (29%)	484 (27%)
30-34.9	185222 (22.5%)	181220 (22.4%)	4002 (23.7%)	3555 (23.5%)	447 (24.9%)
35-39.9	95157 (11.5%)	93011 (11.5%)	2146 (12.7%)	1889 (12.5%)	257 (14.3%)
≥40	69271 (8.4%)	67468 (8.4%)	1803 (10.7%)	1603 (10.6%)	200 (11.1%)
Missing	96813 (11.7%)	95883 (11.9%)	930 (5.5%)	758 (5%)	172 (9.6%)
Smoking	45004 (5.00()	45000 (5.00()	055 (5.70/)	000 (00()	40 (0.70()
Current	45961 (5.6%)	45006 (5.6%)	955 (5.7%)	906 (6%)	49 (2.7%)
Former	255451 (31%)	249578 (30.9%)	5873 (34.8%)	5384 (35.6%)	489 (27.3%)
Never	521628 (63.3%)	511617 (63.3%)	10011 (59.2%)	8764 (58%)	1247 (69.5%)
Missing	1610 (0.2%)	1551 (0.2%)	59 (0.3%)	50 (0.3%)	9 (0.5%)
Blood Pressure (BP) (mm		400 4 (40 07)	400.0 (44.04)	400 4 (44 00)	400.0 (44.00)
Systolic BP (SBP)	129.4 (13.7)	129.4 (13.67)	128.6 (14.91)	128.4 (14.96)	129.9 (14.33)

	Total (N=824,650) Row Percent=	Covid-19 Testing, No (N=807,752)	Covid-19 Testing, Yes (N=16,898)	Test Negative (N=15,104)	Test Positive (N=1,794)
	100%	98%	2.0%	89.4%	10.6%
Diastolic BP (DBP)	72.6 (11.8)	72.6 (11.79)	72.0 (12.53)	71.8 (12.59)	73.3 (11.86)
SBP/DBP	640878 (77.7%)	627469 (77.7%)	13409 (79.4%)	12046 (79.8%)	1363 (76%)
<140/90 SBP/DBP <130/80 Labs	303924 (36.9%)	297026 (36.8%)	6898 (40.8%)	6263 (41.5%)	635 (35.4%)
HbA1c (%)	6.5 (1.37)	6.5 (1.36)	6.6 (1.55)	6.6 (1.52)	6.9 (1.74)
Serum creatinine	0.9 (0.36)	0.9 (0.36)	1.0 (0.48)	1.0 (0.49)	0.9 (0.43)
Total Cholesterol (mg/dL)	169.8 (43.22)	169.9 (43.16)	167.6 (45.88)	167.2 (45.52)	171.3 (48.75)
HDL-C (mg/dL)	50.1 (14.36)	50.1 (14.35)	49.1 (14.98)	49.2 (15.13)	47.6 (13.55)
LDL-C (mg/dL)	95.0 (36.22)	95.0 (36.20)	93.5 (37.09)	93.1 (37.10)	96.7 (36.92)
Triglycerides	139.0 (107.70)	138.9 (107.37)	144.7 (122.74)	143.8 (125.45)	151.7 (97.44)
(mg/dL) Pre-existing conditions Elixhauser comorbidity so	core				
0	68139 (8.3%)	67371 (8.3%)	768 (4.5%)	624 (4.1%)	144 (8%)
1-3	459962 (55.8%)	452970 (56.1%)	6992 (41.4%)	6058 (40.1%)	934 (52.1%)
4+	296549 (36%)	287411 (35.6%)	9138 (54.1%)	8422 (55.8%)	716 (39.9%)
Diabetes	246744 (29.9%)	240318 (29.8%)	6426 (38%)	5726 (37.9%)	700 (39%)
Heart failure	22574 (2.7%)	21391 (2.6%)	1183 (7%)	1119 (7.4%)	64 (3.6%)
CAD	49481 (6%)	47608 (5.9%)	1873 (11.1%)	1758 (11.6%)	115 (6.4%)
CKD	52923 (6.4%)	51094 (6.3%)	1829 (10.8%)	1703 (11.3%)	126 (7%)
Asthma	71275 (8.6%)	68727 (8.5%)	2548 (15.1%)	2420 (16%)	128 (7.1%)
COPD	34268 (4.2%)	32707 (4%)	1561 (9.2%)	1506 (10%)	55 (3.1%)
Pneumonia	32988 (4%)	31373 (3.9%)	1615 (9.6%)	1505 (10%)	110 (6.1%)
Lung disease	6829 (0.8%)	6472 (0.8%)	357 (2.1%)	345 (2.3%)	12 (0.7%)
Arrhythmia	94680 (11.5%)	91422 (11.3%)	3258 (19.3%)	3065 (20.3%)	193 (10.8%)
Valvular Disease	28168 (3.4%)	26991 (3.3%)	1177 (7%)	1121 (7.4%)	56 (3.1%)
Pulmonary	13224 (1.6%)	12562 (1.6%)	662 (3.9%)	623 (4.1%)	39 (2.2%)
Circulation Disease	(,		(,	(,	(
PVD	191739 (23.3%)	186096 (23%)	5643 (33.4%)	5259 (34.8%)	384 (21.4%)
Cancer	8892 (1.1%)	8520 (1.1%)	372 (2.2%)	353 (2.3%)	19 (1.1%)
Paralysis	6010 (0.7%)	5690 (0.7%)	320 (1.9%)	301 (2%)	19 (1.1%)
Neurological Disorders	31001 (3.8%)	29708 (3.7%)	1293 (7.7%)	1209 (8%)	84 (4.7%)
Hypothyroidism	90429 (11%)	88188 (10.9%)	2241 (13.3%)	2087 (13.8%)	154 (8.6%)
Peptic Ulcer	3572 (0.4%)	3388 (0.4%)	184 (1.1%)	174 (1.2%)	10 (0.6%)
AIDS/HIV	1444 (0.2%)	1384 (0.2%)	60 (0.4%)	56 (0.4%)	4 (0.2%)
Lymphoma	4572 (0.6%)	4379 (0.5%)	193 (1.1%)	182 (1.2%)	11 (0.6%)
Solid Tumor	35228 (4.3%)	34092 (4.2%)	1136 (6.7%)	1078 (7.1%)	58 (3.2%)
Rheumatoid Arthritis Mild liver disease	24733 (3%)	23816 (2.9%)	917 (5.4%)	855 (5.7%)	62 (3.5%)
Mild liver disease	43008 (5.2%)	41499 (5.1%)	1509 (8.9%)	1368 (9.1%)	141 (7.9%)
Coagulopathy	21749 (2.6%)	20795 (2.6%)	954 (5.6%)	905 (6%)	49 (2.7%)
Electrolyte Disorders Anemia	81218 (9.8%) 28019 (3.4%)	78096 (9.7%) 26797 (3.3%)	3122 (18.5%) 1222 (7.2%)	2916 (19.3%) 1133 (7.5%)	206 (11.5%) 89 (5%)
,loitila	20010 (0.470)	20.01 (0.070)	1222 (1.270)	1 100 (7.070)	00 (070)

	Total (N=824,650) Row Percent=	Covid-19 Testing, No (N=807,752)	Covid-19 Testing, Yes (N=16,898)	Test Negative (N=15,104)	Test Positive (N=1,794)
	100%	98%	2.0%	89.4%	10.6%
Alcohol Abuse	16412 (2%)	15747 (1.9%)	665 (3.9%)	625 (4.1%)	40 (2.2%)
Drug Abuse	10213 (1.2%)	9684 (1.2%)	529 (3.1%)	504 (3.3%)	25 (1.4%)
Outpatient Antihypertensiv	e Medication Use F	rior to the Index Da	ate		
ACEI	279380 (33.9%)	274502 (34.0%)	4878 (28.9%)	4353 (28.8%)	525 (29.3%)
ARB	159248 (19.3%)	155775 (19.3%)	3473 (20.6%)	3116 (20.6%)	357 (19.9%)
BB or CCB or TD	184365 (22.4%)	180188 (22.3%)	4177 (24.7%)	3835 (25.4%)	342 (19.1%)
Other Antihypertensives	11457 (1.4%)	11080 (1.4%)	377 (2.2%)	355 (2.4%)	22 (1.2%)
No Antihypertensives	190200 (23.1%)	186207 (23.1%)	3993 (23.6%)	3445 (22.8%)	548 (30.5%)
Outpatient Medications Pri	or to the Index Date	Other than Antihy	pertensives		
Lipid lowering	486243 (59%)	476022 (58.9%)	10221 (60.5%)	9198 (60.9%)	1023 (57%)
Antiplatelets	66093 (8%)	64292 (8%)	1801 (10.7%)	1639 (10.9%)	162 (9%)
Nitrates	28039 (3.4%)	26980 (3.3%)	1059 (6.3%)	999 (6.6%)	60 (3.3%)
Antiarrhythmic Agents	7422 (0.9%)	7151 (0.9%)	271 (1.6%)	255 (1.7%)	16 (0.9%)
Insulin	73776 (8.9%)	71346 (8.8%)	2430 (14.4%)	2183 (14.5%)	247 (13.8%)
Oral hypoglycemics	202842 (24.6%)	198119 (24.5%)	4723 (28%)	4146 (27.4%)	577 (32.2%)

Mean (SD) or N (%) are reported. Abbreviations: ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BP = blood pressure; CCB = calcium channel blockers; BB = beta-blockers; CAD = coronary artery disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PVD = peripheral vascular disease; SBP = systolic blood pressure; TD = thiazide diuretics. \*Patients with hypertension was identified from the Kaiser Permanente Southern California (KPSC) hypertension registry as of March 1<sup>st</sup>, 2020. The KPSC hypertension registry includes adult members having one of the following criteria: 1) hypertension diagnosis on the active problem list, 2) ≥2 outpatient visits with a diagnosis code of hypertension within 365 days of each other, 3) ≥1 outpatient visit and ≥1 hospital discharge with a diagnosis code of hypertension within 365 days of the dispensing in the past 6 months and ≥1 outpatient visit with a diagnosis code of hypertension within 365 days of the dispensing date, or 5) ≥1 outpatient visit with a diagnosis code of hypertension and having comorbidities of heart failure, diabetes, coronary artery disease, chronic kidney disease, or cerebrovascular accident.

Table S2. Baseline Characteristics Before and After Matching (between ACEIs and CCB/BB/TD).

	Before Matching		After Ma	After Matching		
	ACEIS	CCB/BB/TD	ACEIs	CCB/BB/TD		
	N=4,875	N=4,170	N=3,598	N=3,598		
Age in years						
18-39	159 (3.3%)	195 (4.7%)	126 (3.5%)	136 (3.8%)		
40-64	2271 (46.6%)	1794 (43%)	1502 (41.7%)	1592 (44.2%)		
65-85	2161 (44.3%)	1840 (44.1%)	1703 (47.3%)	1609 (44.7%)		
85+	284 (5.8%)	341 (8.2%)	267 (7.4%)	261 (7.3%)		
Women	2302 (47.2%)	2557 (61.3%)	1935 (53.8%)	2050 (57%)		
Race/Ethnicity						
White	1896 (38.9%)	1621 (38.9%)	1485 (41.3%)	1421 (39.5%)		
Asian	528 (10.8%)	565 (13.5%)	421 (11.7%)	457 (12.7%)		
Black	603 (12.4%)	758 (18.2%)	559 (15.5%)	555 (15.4%)		
Hispanic	1743 (35.8%)	1136 (27.2%)	1068 (29.7%)	1086 (30.2%)		
Other/Unknown	105 (2.2%)	90 (2.2%)	65 (1.8%)	79 (2.2%)		
BMI category						
<25	782 (16%)	887 (21.3%)	666 (18.5%)	699 (19.4%)		
25-29.9	1403 (28.8%)	1270 (30.5%)	1102 (30.6%)	1101 (30.6%)		
30-34.9	1242 (25.5%)	921 (22.1%)	861 (23.9%)	822 (22.8%)		
35-39.9	645 (13.2%)	535 (12.8%)	472 (13.1%)	464 (12.9%)		
≥40	554 (11.4%)	402 (9.6%)	356 (9.9%)	362 (10.1%)		
Missing	249 (5.1%)	155 (3.7%)	141 (3.9%)	150 (4.2%)		
Smoking status	, ,	, ,		, ,		
Never	2791 (57.3%)	2472 (59.3%)	2114 (58.8%)	2121 (58.9%)		
Current	345 (7.1%)	211 (5.1%)	197 (5.5%)	203 (5.6%)		
Former	1731 (35.5%)	1476 (35.4%)	1279 (35.5%)	1265 (35.2%)		
Missing	8 (0.2%)	11 (0.3%)	8 (0.2%)	9 (0.3%)		
Medicaid indicator	383 (7.9%)	342 (8.2%)	260 (7.2%)	291 (8.1%)		
Household income						
\$0-49k	976 (20%)	753 (18.1%)	643 (17.9%)	666 (18.5%)		
\$50-79k	1861 (38.2%)	1530 (36.7%)	1340 (37.2%)	1330 (37%)		
\$80-99k	984 (20.2%)	856 (20.5%)	751 (20.9%)	737 (20.5%)		
≥\$100k	1054 (21.6%)	1031 (24.7%)	864 (24%)	865 (24%)		
Neighborhood education						
<75%	1487 (30.5%)	1097 (26.3%)	962 (26.7%)	985 (27.4%)		
76-100%	3388 (69.5%)	3073 (73.7%)	2636 (73.3%)	2613 (72.6%)		
Elixhauser score						
0	127 (2.6%)	112 (2.7%)	99 (2.8%)	98 (2.7%)		
1-3	2079 (42.6%)	1744 (41.8%)	1546 (43%)	1515 (42.1%)		
4+	2669 (54.7%)	2314 (55.5%)	1953 (54.3%)	1985 (55.2%)		
Pre-existing comorbidities						
Pneumonia	393 (8.1%)	456 (10.9%)	331 (9.2%)	337 (9.4%)		
Lung disease	82 (1.7%)	105 (2.5%)	71 (2%)	75 (2.1%)		
Diabetes	2231 (45.8%)	1206 (28.9%)	1280 (35.6%)	1162 (32.3%)		
Heart Failure	328 (6.7%)	395 (9.5%)	292 (8.1%)	298 (8.3%)		
Asthma	618 (12.7%)	719 (17.2%)	541 (15%)	545 (15.1%)		
COPD	378 (7.8%)	476 (11.4%)	348 (9.7%)	361 (10%)		
Cancer	342 (7%)	333 (8%)	274 (7.6%)	278 (7.7%)		
Outpatient Medications Prior to						
the Index Date			,			
Antiarrhythmic Agents	73 (1.5%)	112 (2.7%)	70 (1.9%)	71 (2%)		
Antiplatelets	568 (11.7%)	479 (11.5%)	412 (11.5%)	408 (11.3%)		
Insulin	892 (18.3%)	450 (10.8%)	491 (13.6%)	436 (12.1%)		
Lipid lowering agents	3414 (70%)	2454 (58.8%)	2328 (64.7%)	2241 (62.3%)		
Nitrates	318 (6.5%)	322 (7.7%)	280 (7.8%)	265 (7.4%)		
Oral hypoglycemics	1805 (37%)	821 (19.7%)	887 (24.7%)	813 (22.6%)		

SBP/DBP <140/90 mm Hg	4004 (82.1%)	3419 (82%)	2952 (82%)	2941 (81.7%)
SBP/DBP <130/80 mm Hg	2130 (43.7%)	1775 (42.6%)	1586 (44.1%)	1540 (42.8%)
Labs				
Serum creatinine	1.0 (0.39)	1.0 (0.56)	1.0 (0.41)	1.0 (0.57)
HDL-C (mg/dL)	47.9 (13.97)	50.2 (16.14)	49.4 (14.36)	49.5 (15.57)
HbA1c (%)	6.8 (1.62)	6.3 (1.35)	6.5 (1.44)	6.4 (1.39)
LDL-C (mg/dL)	90.8 (36.39)	94.7 (37.33)	92.5 (35.71)	93.9 (37.31)
Total Cholesterol (mg/dL)	164.0 (45.91)	169.6 (46.74)	166.2 (43.50)	168.4 (46.64)
Triglycerides (mg/dL)	146.1 (107.58)	138.7 (107.34)	136.9 (81.82)	141.1 (111.73)

Mean (SD) or N (%) are reported. Abbreviations: ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BP = blood pressure; CCB = calcium channel blockers; BB = beta-blockers; CAD = coronary artery disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PVD = peripheral vascular disease; SBP = systolic blood pressure; TD = thiazide diuretics.

Table S3. Baseline Characteristics Before and After Matching (between ARBs and CCB/BBTD).

	Before Matching		After Matching		
	ARB	CCB/BB/TD	ARB	CCB/BB/TD	
	N=3,468	N=4,170	N=2,945	N=2,945	
Age in years					
18-39	76 (2.2%)	195 (4.7%)	73 (2.5%)	77 (2.6%)	
40-64	1445 (41.7%)	1794 (43%)	1199 (40.7%)	1277 (43.4%)	
65-85	1721 (49.6%)	1840 (44.1%)	1456 (49.4%)	1378 (46.8%)	
85+	226 (6.5%)	341 (8.2%)	217 (7.4%)	213 (7.2%)	
Women	2065 (59.5%)	2557 (61.3%)	1766 (60%)	1763 (59.9%)	
Race/Ethnicity					
White	1149 (33.1%)	1621 (38.9%)	1072 (36.4%)	1064 (36.1%)	
Asian	698 (20.1%)	565 (13.5%)	477 (16.2%)	504 (17.1%)	
Black	469 (13.5%)	758 (18.2%)	456 (15.5%)	442 (15%)	
Hispanic	1068 (30.8%)	1136 (27.2%)	877 (29.8%)	862 (29.3%)	
Other/Unknown	84 (2.4%)	90 (2.2%)	63 (2.1%)	73 (2.5%)	
BMI category	, ,	, ,	, ,	,	
<25	554 (16%)	887 (21.3%)	518 (17.6%)	510 (17.3%)	
25-29.9	990 (28.5%)	1270 (30.5%)	872 (29.6%)	887 (30.1%)	
30-34.9	925 (26.7%)	921 (22.1%)	721 (24.5%)	727 (24.7%)	
35-39.9	487 (14%)	535 (12.8%)	409 (13.9%)	410 (13.9%)	
≥40	392 (11.3%)	402 (9.6%)	319 (10.8%)	306 (10.4%)	
Missing	120 (3.5%)	155 (3.7%)	106 (3.6%)	105 (3.6%)	
Smoking status	,	,		,	
Never	2134 (61.5%)	2472 (59.3%)	1778 (60.4%)	1775 (60.3%)	
Current	132 (3.8%)	211 (5.1%) <sup>′</sup>	120 (4.1%)	133 (4.5%)	
Former	1198 (34.5%)	1476 (35.4%)	1043 (35.4%)	1034 (35.1%)	
Missing	4 (0.1%)	11 (0.3%)	4 (0.1%)	3 (0.1%)	
Medicaid indicator	294 (8.5%)	342 (8.2%)	223 (7.6%)	241 (8.2%)	
Household income		(		(= ==,	
\$0-49k	635 (18.3%)	753 (18.1%)	526 (17.9%)	538 (18.3%)	
\$50-79k	1281 (36.9%)	1530 (36.7%)	1079 (36.6%)	1073 (36.4%)	
\$80-99k	772 (22.3%)	856 (20.5%)	634 (21.5%)	641 (21.8%) <sup>´</sup>	
≥\$100k	780 (22.5%)	1031 (24.7%)	706 (24%)	693 (23.5%)	
Neighborhood education	,	,	, ,	,	
<75%	969 (27.9%)	1097 (26.3%)	777 (26.4%)	784 (26.6%)	
76-100%	2499 (72.1%)	3073 (73.7%)	2168 (73.6%)	2161 (73.4%)	
Elixhauser score				- (,	
0	57 (1.6%)	112 (2.7%)	56 (1.9%)	72 (2.4%)	
1-3	1263 (36.4%)	1744 (41.8%)	1112 (37.8%)	1156 (39.3%)	
4+	2148 (61.9%)	2314 (55.5%)	1777 (60.3%)	1717 (58.3%)	
Pre-existing comorbidities		(/	()	(,	
Pneumonia	340 (9.8%)	456 (10.9%)	299 (10.2%)	296 (10.1%)	
Lung disease	83 (2.4%)	105 (2.5%)	77 (2.6%)	77 (2.6%)	
Diabetes	1708 (49.3%)	1206 (28.9%)	1202 (40.8%)	1134 (38.5%)	
Heart Failure	281 (8.1%)	395 (9.5%)	264 (9%)	268 (9.1%)	
Asthma	620 (17.9%)	719 (17.2%)	531 (18%)	504 (17.1%)	
COPD	366 (10.6%)	476 (11.4%)	339 (11.5%)	326 (11.1%)	
Cancer	236 (6.8%)	333 (8%)	215 (7.3%)	217 (7.4%)	
Outpatient Medications Prior	(,	(/	,	/	
to the Index Date					
Antiarrhythmic Agents	45 (1.3%)	112 (2.7%)	45 (1.5%)	49 (1.7%)	
Antiplatelets	470 (13.6%)	479 (11.5%)	384 (13%)	367 (12.5%)	
Insulin	643 (18.5%)	450 (10.8%)	456 (15.5%)	427 (14.5%)	
Lipid lowering agents	2525 (72.8%)	2454 (58.8%)	2032 (69%)	1967 (66.8%)	
Nitrates	291 (8.4%)	322 (7.7%)	254 (8.6%)	244 (8.3%)	
Oral hypoglycemics	1275 (36.8%)	821 (19.7%)	833 (28.3%)	790 (26.8%)	

SBP/DBP <140/90 mm Hg	2767 (79.8%)	3419 (82%)	2359 (80.1%)	2385 (81%)
SBP/DBP <130/80 mm Hg	1369 (39.5%)	1775 (42.6%)	1175 (39.9%)	1240 (42.1%)
Labs				
Serum creatinine	1.0 (0.51)	1.0 (0.56)	1.0 (0.43)	1.0 (0.60)
HDL-C (mg/dL)	49.0 (14.52)	50.2 (16.14)	49.9 (14.96)	49.4 (15.60)
HbA1c (%)	6.7 (1.40)	6.3 (1.35)	6.6 (1.34)	6.5 (1.45)
LDL-C (mg/dL)	89.1 (34.93)	94.7 (37.33)	90.7 (35.27)	92.8 (37.96)
Total Cholesterol (mg/dL)	163.7 (42.78)	169.6 (46.74)	165.2 (42.86)	167.3 (47.07)
Triglycerides (mg/dL)	151.1 (156.94)	138.7 (107.34)	145.2 (159.27)	140.5 (94.59)

Mean (SD) or N (%) are reported. ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BP = blood pressure; CCB = calcium channel blockers; BB = beta-blockers; CAD = coronary artery disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PVD = peripheral vascular disease; SBP = systolic blood pressure; TD = thiazide diuretics.

Table S4. Baseline Characteristics Before and After Matching (between No Antihypertensive Medications and CCB/BB/TD).

	Before Matching		After Ma	tching
	No		No	
	Antihypertensive Medications N=3,990	<b>CCB/BB/TD</b> N=4,170	Antihypertensive Medications N=3,110	<b>CCB/BB/TD</b> N=3,110
Age in years	,,,,,,,	, -	-, -	-, -
18-39	335 (8.4%)	195 (4.7%)	192 (6.2%)	143 (4.6%)
40-64	2031 (50.9%)	1794 (43%)	1507 (48.5%)	1531 (49.2%)
65-85	1321 (33.1%)	1840 (44.1%)	1173 (37.7%)	1176 (37.8%)
85+	303 (7.6%)	341 (8.2%)	238 (7.7%)	260 (8.4%)
Women	2215 (55.5%)	2557 (61.3%)	1879 (60.4%)	1850 (59.5%)
Race/Ethnicity	,	, ,	, ,	,
White	1314 (32.9%)	1621 (38.9%)	1125 (36.2%)	1134 (36.5%)
Asian	495 (12.4%)	565 (13.5%)	415 (13.3%)	387 (12.4%)
Black	547 (13.7%)	758 (18.2%)	487 (15.7%)	503 (16.2%)
Hispanic	1546 (38.7%)	1136 (27.2%)	1010 (32.5%)	1026 (33%)
Other/Unknown	88 (2.2%)	90 (2.2%)	73 (2.3%)	60 (1.9%)
BMI category	(=:=,0)	(=:=/0)	(=10,75)	(11070)
<25	851 (21.3%)	887 (21.3%)	688 (22.1%)	700 (22.5%)
25-29.9	1070 (26.8%)	1270 (30.5%)	909 (29.2%)	886 (28.5%)
30-34.9	827 (20.7%)	921 (22.1%)	666 (21.4%)	666 (21.4%)
35-39.9	435 (10.9%)	535 (12.8%)	385 (12.4%)	371 (11.9%)
≥40	412 (10.3%)	402 (9.6%)	308 (9.9%)	315 (10.1%)
Missing	395 (9.9%)	155 (3.7%)	154 (5%)	172 (5.5%)
Smoking status	000 (0.070)	100 (0.1 70)	101 (070)	112 (0.070)
Never	2434 (61%)	2472 (59.3%)	1895 (60.9%)	1889 (60.7%)
Current	245 (6.1%)	211 (5.1%)	177 (5.7%)	175 (5.6%)
Former	1275 (32%)	1476 (35.4%)	1027 (33%)	1030 (33.1%)
Missing	36 (0.9%)	11 (0.3%)	11 (0.4%)	16 (0.5%)
Medicaid indicator	457 (11.5%)	342 (8.2%)	296 (9.5%)	283 (9.1%)
Household income	437 (11.370)	042 (0.270)	230 (3.570)	200 (0.170)
\$0-49k	922 (23.1%)	753 (18.1%)	600 (19.3%)	623 (20%)
\$50-79k	1536 (38.5%)	1530 (36.7%)	1195 (38.4%)	1194 (38.4%)
\$80-99k	749 (18.8%)	856 (20.5%)	615 (19.8%)	616 (19.8%)
≥\$100k	783 (19.6%)	1031 (24.7%)	700 (22.5%)	677 (21.8%)
Neighborhood education	700 (10.070)	1001 (24.770)	700 (22.070)	011 (21.070)
<75%	1266 (31.7%)	1097 (26.3%)	885 (28.5%)	894 (28.7%)
76-100%	2724 (68.3%)	3073 (73.7%)	2225 (71.5%)	2216 (71.3%)
Elixhauser score	2724 (00.070)	3073 (73.770)	2223 (71.570)	2210 (11.070)
0	455 (11.4%)	112 (2.7%)	105 (3.4%)	251 (8.1%)
1-3	1820 (45.6%)	1744 (41.8%)	1450 (46.6%)	1400 (45%)
4+	1715 (43%)	2314 (55.5%)	1555 (50%)	1459 (46.9%)
Pre-existing comorbidities	17 10 (4070)	2014 (00.070)	1000 (0070)	1400 (40.070)
Pneumonia	356 (8.9%)	456 (10.9%)	294 (9.5%)	282 (9.1%)
Lung disease	69 (1.7%)	105 (2.5%)	58 (1.9%)	59 (1.9%)
Diabetes	1129 (28.3%)	1206 (28.9%)	859 (27.6%)	893 (28.7%)
Heart Failure	105 (2.6%)	395 (9.5%)	114 (3.7%)	99 (3.2%)
Asthma	511 (12.8%)	719 (17.2%)	459 (14.8%)	453 (14.6%)
COPD	254 (6.4%)	476 (11.4%)	242 (7.8%)	238 (7.7%)
Cancer	233 (5.8%)	333 (8%)	217 (7%)	213 (6.8%)
Outpatient Medications Prior	200 (0.070)	000 (070)	217 (170)	210 (0.070)
to the Index Date				
Antiarrhythmic Agents	00 (0 =0)	110 (6 =51)	00 ((0))	0= (0.55)
, and army annie Agents	26 (0.7%)	112 (2.7%)	30 (1%)	25 (0.8%)
Antiplatelets	239 (6%)	479 (11.5%)	240 (7.7%)	227 (7.3%)
Insulin	386 (9.7%)	450 (10.8%)	300 (9.6%)	322 (10.4%)
Lipid lowering agents	1577 (39.5%)	2454 (58.8%)	1508 (48.5%)	1460 (46.9%)

Nitrates	88 (2.2%)	322 (7.7%)	98 (3.2%)	88 (2.8%)
Oral hypoglycemics	739 (18.5%)	821 (19.7%)	592 (19%)	587 (18.9%)
SBP/DBP <140/90 mm Hg	2881 (72.2%)	3419 (82%)	2459 (79.1%)	2404 (77.3%)
SBP/DBP <130/80 mm Hg	1416 (35.5%)	1775 (42.6%)	1238 (39.8%)	1197 (38.5%)
Labs				
Serum creatinine	0.9 (0.44)	1.0 (0.56)	1.0 (0.55)	0.9 (0.43)
HDL-C (mg/dL)	49.3 (15.18)	50.2 (16.14)	50.3 (16.23)	50.1 (15.42)
HbA1c (%)	6.6 (1.75)	6.3 (1.35)	6.3 (1.36)	6.6 (1.70)
LDL-C (mg/dL)	101.5 (38.96)	94.7 (37.33)	97.9 (37.08)	101.0 (40.03)
Total Cholesterol (mg/dL)	175.7 (46.96)	169.6 (46.74)	173.1 (46.48)	175.3 (47.92)
Triglycerides (mg/dL)	145.0 (122.04)	138.7 (107.34)	141.0 (114.92)	140.3 (113.01)


Mean (SD) or N (%) are reported. ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BP = blood pressure; CCB = calcium channel blockers; BB = beta-blockers; CAD = coronary artery disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PVD = peripheral vascular disease; SBP = systolic blood pressure; TD = thiazide diuretics.

Table S5. Odds Ratio (95% CI) of Covid-19 Infection Associated with Antihypertensive Drug Exposure Among All Patients with Hypertension (Outcome = Covid-19 Infection; Reference group: CCB/BB/TD).

	Crude OR	Age- and Sex-	Multivariable
		Adjusted OR	Adjusted OR*
ACEI	1.01	0.98	0.92
	(0.88-1.16)	(0.86-1.13)	(0.80-1.06)
ARB	1.20	1.15	1.04
	(1.04-1.40)	(0.99-1.33)	(0.89-1.21)
No Antihypertensive Medication	1.55	1.38	1.44
	(1.36-1.78)	(1.21-1.59)	(1.25-1.65)


ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BB = beta blocker; CCB = calcium channel blocker; \*Patient demographics, neighborhood income and education, insurance, body mass index, smoking status, outpatient blood pressure, baseline comorbidities, and outpatient medication use were adjusted.

Figure S1. Study Cohort.



KPSC = Kaiser Permanente Southern California; Dx = diagnosis; COVID-19 Testing period = March 1-May 6, 2020; Test positive = Ever positive results

Figure S2. Propensity Score Distribution.








Figure S3. Standardized Mean Difference Comparison Before and After Propensity Score Matching among Patients Taking ACEI or BB/CCB/TD.




Blue triangle represents standardized mean difference (SMD) before matching, and orange circle represents SMD after matching. Hypertension refers to ≥1 outpatient visits with hypertension diagnosis codes.

Figure S4. Standardized Mean Difference Comparison Before and After Propensity Score Matching among Patients Taking ARB or BB/CCB/TD.



Blue triangle represents standardized mean difference (SMD) before matching, and orange circle represents SMD after matching. Hypertension refers to ≥1 outpatient visits with hypertension diagnosis codes.

Figure S5. Standardized Mean Difference Comparison Before and After Propensity Score Matching among Patients Not Taking Antihypertensive Medications or Taking BB/CCB/TD.



Blue triangle represents standardized mean difference (SMD) before matching, and orange circle represents SMD after matching. Hypertension refers to ≥1 outpatient visits with hypertension diagnosis codes.